Efficacy and safety of elranatamab monotherapy in patients with relapsed/refractory multiple myeloma: a post-hoc subgroup analysis from MagnetisMM-3 with modified eligibility criteria

被引：0
|
作者：
Raab, Marc [1 ]
Manier, Salomon [2 ]
Prince, H. Miles [3 ]
Nooka, Ajay [4 ]
Kaedbey, Rayan [5 ]
Hillengass, Jens [6 ]
Ishida, Tadao [7 ]
Sullivan, Sharon [8 ]
Conte, Umberto [8 ]
Leip, Eric [8 ]
Viqueira, Andrea [9 ]
Raje, Noopur [10 ]
机构：
[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany
[2] Univ Lille, Ctr Hosp Univ Lille, Lille, France
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA USA
[5] McGill Univ, Montreal, PQ, Canada
[6] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[7] Japanese Red Cross Med Ctr, Tokyo, Japan
[8] Pfizer Inc, New York, NY USA
[9] Pfizer SLU, Madrid, Spain
[10] Massachusetts Gen Hosp, Boston, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-307
引用
收藏
页码：S207 / S208
页数：2
相关论文
共 50 条
  • [1] A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma
    Noopur, Raje
    Xavier, Leleu
    Alexander, Lesokhin M.
    Mohamed, Mohty
    Ajay, Nooka
    Eric, Leip
    Umberto, Conte
    Andrea, Vlqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S17 - S18
  • [2] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Cohort a of MagnetisMM-3
    Shay, Gemma
    Bahlis, Nizar
    Tomasson, Michael H.
    Mohty, Mohamad
    Niesvizky, Ruben
    Nooka, Ajay
    Manier, Salomon
    Maisel, Christopher
    Jethava, Yogesh
    Martinez-Lopez, Joaquin
    Prince, H. Miles
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Koehne, Guenther
    Touzeau, Cyrille
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Leip, Eric
    Sullivan, Sharon
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 16 - 17
  • [3] Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3
    Raje, Noopur
    Leleu, Xavier
    Lesokhin, Alexander
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S497
  • [4] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Raab, M. S.
    Haenel, M.
    Raje, N.
    Leleu, X.
    Lesokhin, A.
    Mohty, M.
    Nooka, A. K.
    Leip, E.
    Conte, U.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 80 - 81
  • [5] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies
    Varshavsky-Yanovsky, Asya
    Jethava, Yogesh
    Stevens, Don A.
    Nooka, Ajay K.
    Stiff, Patrick J.
    Perez-Cruz, Isabel
    Leip, Eric
    Lesokhin, Alexander
    BLOOD, 2023, 142
  • [7] Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3
    Iida, Shinsuke
    Ito, Satoshi
    Yokoyama, Hisayuki
    Ishida, Tadao
    Nagai, Yuya
    Handa, Hiroshi
    Ito, Shigeki
    Kamei, Yoichi
    Nakamura, Masatoshi
    Suzuki, Kenshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (09) : 991 - 1000
  • [8] Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
    Tomasson, Michael
    Iida, Shinsuke
    Niesvizky, Ruben
    Mohty, Mohamad
    Bahlis, Nizar J.
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Rodriguez Otero, Paula
    Prince, H. Miles
    Viqueira, Andrea
    Leip, Eric
    Conte, Umberto
    Sullivan, Sharon T.
    Lesokhin, Alexander
    BLOOD, 2023, 142
  • [9] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
    Alexander M. Lesokhin
    Michael H. Tomasson
    Bertrand Arnulf
    Nizar J. Bahlis
    H. Miles Prince
    Ruben Niesvizky
    Paula Rodrίguez-Otero
    Joaquin Martinez-Lopez
    Guenther Koehne
    Cyrille Touzeau
    Yogesh Jethava
    Hang Quach
    Julien Depaus
    Hisayuki Yokoyama
    Afshin Eli Gabayan
    Don A. Stevens
    Ajay K. Nooka
    Salomon Manier
    Noopur Raje
    Shinsuke Iida
    Marc-Steffen Raab
    Emma Searle
    Eric Leip
    Sharon T. Sullivan
    Umberto Conte
    Mohamed Elmeliegy
    Akos Czibere
    Andrea Viqueira
    Mohamad Mohty
    Nature Medicine, 2023, 29 : 2259 - 2267
  • [10] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
    Lesokhin, Alexander H.
    Tomasson, Michael
    Arnulf, Bertrand J.
    Bahlis, Nizar
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Touzeau, Cyrille
    Jethava, Yogesh
    Quach, Hang
    Depaus, Julien
    Yokoyama, Hisayuki
    Gabayan, Afshin Eli A.
    Stevens, Don K.
    Nooka, Ajay
    Manier, Salomon
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Searle, Emma
    Leip, Eric T.
    Sullivan, Sharon
    Conte, Umberto
    Elmeliegy, Mohamed
    Czibere, Akos
    Viqueira, Andrea
    Mohty, Mohamad
    NATURE MEDICINE, 2023, 29 (09) : 2259 - +
12345